Indeed, PARP1/2 inhibitors such as olaparib have been clinically used for treating solid tumors, including ovarian, breast, and prostate cancers (Bastos et al. 2024; Luo et al. 2024). This evidence concerns the gene PARP1 and prostate cancer.